ICON Public Limited (NASDAQ:ICLR) Receives Average Rating of "Moderate Buy" from Analysts

Shares of ICON Public Limited (NASDAQ:ICLR - Get Free Report) have been assigned an average rating of "Moderate Buy" from the fifteen brokerages that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $279.17.

Several equities research analysts have commented on the stock. Citigroup dropped their price target on shares of ICON Public from $300.00 to $290.00 and set a "buy" rating on the stock in a research report on Monday, January 6th. Royal Bank of Canada restated an "outperform" rating and set a $263.00 price objective on shares of ICON Public in a report on Wednesday, January 15th. Leerink Partners restated an "outperform" rating and set a $255.00 price objective (down previously from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. William Blair restated an "outperform" rating on shares of ICON Public in a report on Tuesday, January 14th. Finally, Truist Financial cut their price objective on ICON Public from $284.00 to $262.00 and set a "buy" rating on the stock in a report on Thursday, February 13th.

ICON Public Stock Performance

Shares of NASDAQ ICLR traded up $0.26 during midday trading on Tuesday, reaching $186.03. 788,240 shares of the company traded hands, compared to its average volume of 826,131. ICON Public has a 52 week low of $174.93 and a 52 week high of $347.72. The stock has a 50-day moving average price of $195.57 and a 200 day moving average price of $229.43. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.26 and a quick ratio of 1.34. The company has a market cap of $15.02 billion, a price-to-earnings ratio of 19.52, a PEG ratio of 1.86 and a beta of 1.21.

Remove Ads

ICON Public (NASDAQ:ICLR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The firm had revenue of $2.04 billion for the quarter, compared to analysts' expectations of $2.04 billion. Sell-side analysts anticipate that ICON Public will post 13.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Several large investors have recently made changes to their positions in the company. Foyston Gordon & Payne Inc grew its stake in shares of ICON Public by 27.3% in the 4th quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company's stock valued at $10,845,000 after buying an additional 11,089 shares in the last quarter. Captrust Financial Advisors grew its stake in shares of ICON Public by 2.0% in the 4th quarter. Captrust Financial Advisors now owns 35,301 shares of the medical research company's stock valued at $7,403,000 after buying an additional 701 shares in the last quarter. State of Tennessee Department of Treasury grew its stake in shares of ICON Public by 1.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company's stock valued at $33,333,000 after buying an additional 1,600 shares in the last quarter. Motley Fool Wealth Management LLC grew its stake in shares of ICON Public by 2.3% in the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company's stock valued at $13,342,000 after buying an additional 1,466 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its stake in shares of ICON Public by 128.2% in the 4th quarter. Whittier Trust Co. of Nevada Inc. now owns 1,166 shares of the medical research company's stock valued at $245,000 after buying an additional 655 shares in the last quarter. Institutional investors own 95.61% of the company's stock.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.